
Index

A

- Adipose derived adult mesenchymal stem cell (ADASC), 373, 405
- Adipose tissue-derived MSCs (AT-MSCs), 236
- Adipose tissue mesothelial cell (ATMC), 138
- Adult stem cells, 42, 478
- Advanced therapy medicinal products (ATMPs), 48, 91
- Allogeneic limbal transplant, 287
- Alpha smooth muscle actin (α -SMA), 304, 307, 308, 493
- Amniotic membrane (AM), 63, 128, 429
- Amniotic membranes, 293
- Amniotic membrane transplantation, 301
- ANGEL®, 327
- Animal model, 152
 - cat, 448
 - choice of, 443
 - monkey, 449
 - pig, 448
 - rabbit, 444
 - rodent, 444
 - sheep, 449
- Anterior chamber associated immune deviation (ACAID), 441, 443
- Anterior chamber injection, 411
- Anterior lens capsule, 429
- Anti-angiogenic function, 239
- Anti-inflammatory action, 238
- Aquaporin 1 (AQP1), 482
- Aqueous deficient DED (ADDED), 328
- Artificial cell-free device, 155
- Autologous eye-platelet rich plasma (E-PRP), 19
- Autologous limbal stem cell product, quality control for, 91
- Autologous limbal stem cell transplants (ALSCT), 82
- Autologous serum eye drops (ASE), 81
- Autologous transplantation
 - European marketing authorisation, 93
 - good manufacturing practice, 91
 - limbal stem cell, 92–93
 - manufactured product, 92
 - quality control, 91–92

B

- Barrier function, corneal endothelium, 421
- Basic fibroblast growth factor (bFGF), 112
- Biodegradable polymers, 466
- Biological cell carriers, 487
- Blindness, 390
- Bone marrow-derived endothelial progenitor cells (BEPC), 137, 489
- Bone marrow-derived MSCs (BM-MSCs), 234
- Bone marrow mesenchymal stem cell (BM-MSC), 404
- Bone morphogenic protein 4 (BMP4), 270
- Bovine pituitary extract (BPE), 112
- Bowman's layer, 13, 388
- Bullous keratopathy (BK), 166

C

- Calcineurin inhibitors, 294
- Cancer stem cells (CSCs), 51–52
- Canonical Wnt signaling, 430
- Carbon dioxide, 422
- Cataract extraction, 464
- CD44, 117
- CD56, 423
- CD109, 423
- CD 166, 422
- CD200, 117, 422
- CD248, 423
- Cell-based medicinal products (CBMP), 399
- Cell-based therapy, 467–468
- Cell carriers
 - biological, 487
 - synthetic, 489
- Cell-injection therapy, 457
 - for bullous keratopathy patient, 458
 - in failed graft eye, 459
 - ROCK inhibitor, 457
 - safety and efficacy of, 459
 - specular microscopy, 460
 - surgical procedure, 457
- Cell migration, 306

- Cell therapy
 with adult tissue progenitors, 264
 clinical application, 271
 using cultivated oral mucosal epithelial transplant (COMET), 225–228
 using ex vivo cultured limbal cells, 221–224
 using induced pluripotent stem cell, 263–273
- Cell types, 109
- Cellular injection
 animal studies of, 492
 endothelial dysfunction, 491
- CEnPC, *see* Corneal endothelial progenitor cell (CEnPC)
- Chitosan, 466
- CLAU, *see* Conjunctival limbal autograft (CLAU)
- CLET, *see* Cultivated limbal epithelial transplantation (CLET)
- CLRN1, 424
- Collagen, 27, 489
- Collagen II production, 152
 dystrophic cornea biomechanical property, 151
 in human tissue, 149
 in vivo model, 151
 in keratoconic tissue, 150
- Collagen type-1, 351
- COMET, *see* Cultivated oral mucosal epithelial transplantation (COMET)
- Committee for Advanced Therapies (CAT), 49
- Confocal microscopy
 cell counting methods
 ADAS cell, 373
 automated cell counting, 371
 decellularized lamina, 374
 difficulty, 375
 manual cell counting, 371–373
 recellularized lamina, 375
 corneal density calculation, 375
 corneal stroma
 automatic cell counting, 384
 patients with decellularized lamina, 377–381
 patients with recellularized lamina, 380–383
 patients with transplanted ADAS, 375–376
 sample, 367–371
 handling difficulty, 366
 preparation, 364–366
- Confocal ophthalmoscopy, 441
- Conjunctival epithelium
 goblet cells, 184
 innervation, 186
 mucin, 184
 tear film, 185–186
- Conjunctival invasion, 300
- Conjunctival limbal autograft (CLAU), 156
 indication, 156
 LSCD, 156
 ocular surface neoplasia, 157
 outcome, 157
 pterygium, 157
- Conjunctival transplantation, 191, 195–198
- Conjunctivalisation, 301
- Connexins, 178
- Connexon, 178
- Cornea, 419
 anatomical dimensions, 3
 biometrics and structure, 350
 Bowman's layer, 388
 Descemet's membrane, 388
 diseases, 23
 embryology, 3
 endothelium, 388
 epithelium, 388
 integrity and transparency, 57
 stroma, 388
 transparency, 388
- Corneal endothelial cell (CEnC), 58, 109, 481, 485, 486
 biology, 455–456
 cell-injection therapy, 457–458
 for bullous keratopathy patient, 458–459
 in failed graft eye, 459
 product development, 458
 specular microscopy, 460
 surgical procedure, 457
 culture for clinical application, 456
 sheet transplantation, 456–457
- Corneal endothelial cell loss, prevention
 RTA 408 ophthalmic suspension, 464
 sulforaphane, 464
- Corneal endothelial progenitor cell (CEnPC), 58
 function, 66
 obtaining methods
 adherent culture of single cells, 67
 application, 69
 culture onto biological and biosynthetic substrate, 68
 explant culture, 68
 suspension culture, 68
 study, 66
- Corneal endothelium, 14, 26, 425
 changes in cell density and size, 421
 3D mapping proteins, 423
 embryology, 419–420
 functional activity, 8
 human, 419, 420
 immunohistochemistry of, 422–424
 mitotic activity, 9
 morphology, 420–421
 physiology
 barrier function, 421
 pump function, 422
 secretory function, 422
 ZO-1 staining for rabbit cells, 423
- Corneal epithelial cells (CEC), 13, 77, 422, 479
 apical cell layer, 4
 basal cell layer, 4
 hypothesis, 6
 innervation, 5
 limbus, 6
 mass, 183
 regenerate, 78
 stem cell based therapy, 155
- Corneal epithelial stem cells, 179

- Corneal graft rejection
 - clinical criteria, 440
 - from animal models, 441
 - Corneal healing process
 - attachment, 17
 - cytokines, 14
 - endothelial regeneration, physiological mechanism of, 19–21
 - epithelial cell migration, 16
 - growth factor
 - autologous eye-platelet rich plasma, 19
 - epidermal, 14, 18
 - fibroblast, 15
 - hepatocyte, 15
 - insulin-like growth factor, 16, 18
 - keratinocyte growth factor 1, 15
 - nerve growth factor, 15, 18
 - platelet-derived growth factor, 15
 - transforming growth factor- β , 15
 - latent phases, 16
 - proliferation and differentiation, 16
 - Corneal layers, 176
 - Corneal neovascularization, 23
 - Corneal opacification, 440, 441, 444
 - Corneal scraping, 301
 - Corneal stroma. *See also* Corneal stromal stem cells (CSSC), 7–8
 - Corneal stromal stem cell (CSSC), 57, 404
 - with basic fibroblast growth factor, 64
 - culturing, 104–105
 - differentiation
 - into keratocytes, 101–102
 - into non-ocular cells, 101
 - embryonic origin, 100
 - expanding methods
 - explant culture, 65
 - plastic adherent culture, 65
 - suspension culture, 66
 - function, 103
 - gene expression, 101
 - immune reactions of, 103
 - interactions, 103
 - isolation from limbal biopsy, 104
 - limbal niche, confocal microscopy of, 105–106
 - localization of, 102
 - mesenchymal origin, 101
 - obtaining methods, 64
 - primary isolation, in humans, 100
 - progenitor potential of, 100
 - properties, 101
 - Corneal wound healing, 237
 - clinical trial, 398–400
 - epithelial injury, 392
 - hLMSC, 395–398
 - limbus and the stem cell, 390–391
 - MSC limitations, 394
 - myofibroblast migration and differentiation, 392
 - preclinical trial, 394–395
 - stem cell-based therapy, 393
 - adipose tissue, 393
 - bone marrow, 393
 - dental pulp, 394
 - embryonic, 394
 - induced pluripotent stem cell, 394
 - neural stem cell, 394
 - umbilical cord, 394
 - stromal remodelling, 392
 - Corneoscleral rims, 158, 302, 303, 427
 - Coxsackieadenovirus receptor (CAR), 423
 - Cryoablation, 445
 - Cultivated limbal epithelial transplantation (CLET), 160–161, 222, 223
 - biopsy harvesting, 285
 - culture method
 - scaffold, 284
 - technique, 285
 - graft transplantation, 285
 - post-operative management
 - additional, 287
 - early, 286
 - pre-operative assessment
 - indications, 278–281
 - supplementary examinations, 281–283
 - Cultivated oral mucosal epithelial transplantation (COMET), 161–163
 - clinical results, 227
 - development, 226
 - keratoplasty, 227–228
 - surgery, 226–227
 - Cultured limbal epithelial transplantation (CLET), 25
 - Current stem cell based therapy, 155
 - conjunctival limbal autograft, 156
 - indication, 156
 - LSCD, 156
 - ocular surface neoplasia, 157
 - outcome, 157
 - pterygium, 157
 - cultivated limbal epithelial transplantation, 160–161
 - cultivated oral mucosal epithelial transplantation, 161–163
 - keratolimbal allograft, 158
 - living-related conjunctival limbal allograft, 158–160
 - postoperative complication, 163–164
 - simple limbal epithelial transplantation, 161
 - Cyclophosphamide, 449
 - Cyclosporine A (CsA), 295
 - Cytokeratin(s), 178, 181
 - Cytokeratin intermediate filaments, 5
 - Cytokine, 392
 - Cytoskeleton, 178
- D**
- Decellularization, 88, 489
 - Decellularized lamina
 - anterior face, 377–379
 - collagen matrix morphology, 378
 - posterior face, 377–379
 - reflective peripheral structures, 380
 - transition zone, 380, 385

- Degranulation, 318
 Demoglein, 177
 Dendritic cells, 8
 Dental pulp-derived MSCs (DP-MSCs), 236
 Dental pulp stem cell (DPSC), 394
 Descemet membrane (DM), 8, 13, 112, 388, 420, 428, 463, 488
 Descemet membrane endothelial transfer (DMET), 20, 465
 Descemet's membrane endothelial keratoplasty (DMEK), 464
 Descemet stripping automated endothelial keratoplasty (DSAEK), 445, 487
 Descemet's stripping endothelial keratoplasty (DSEK), 464, 490
 Descemetorhexis, 465
 Desmocollins, 177
 Desmoglein 3, 182
 Desmosomes, 177
 Devitalization, 445
 Direct cell labelling methods, 440
 Direct cellular reprogramming, 267
 Direct compression injury, 308
 Direct monolayer implantation, 487
 Donut excimer laser ablation model, 302
 Dry eye disease, 225
 DSAEK, *see* Descemet stripping automated endothelial keratoplasty (DSAEK)
 Dua-Fine layer, 355
 Dua's layer, 13
 Dulbecco's phosphate-buffered saline (DPBS), 84
- E**
- E-cadherin, 467
 Ectatic disorder, 403
 Embryonic stem cell (ESC), 41, 123, 394, 404, 405, 468
 corneal endothelium regeneration, 135
 corneal epithelium regeneration, 124–127
 corneal stroma regeneration, 131–133
 Embryonic tissue, 477
 Endosialin, 423
 Endothelial cell, *see* Human corneal endothelial cell (HCEnC)
 Endothelial cell density (ECD), 425, 463
 Endothelial cell therapy, 486
 Endothelial decompensation, 464
 Endothelial dysfunction
 animal models, 485–487
 carrier implantation
 animal studies of, 491–494
 biological cell carriers, 487–489
 synthetic cell carriers, 489–491
 cellular injection, 491, 493
 animal studies of, 492
 direct monolayer implantation, 487
 management, 463–464
 Endothelial keratoplasty (EK), 426, 455, 464
 Endothelial-mesenchymal transition (EMT), 110, 430, 467
 Endothelial regeneration, 481–482
- Endothelial transplantation
 animal models, 438
 cat, 448
 choice of, 443–444
 monkey, 449
 pig, 448
 rabbit, 444–448
 rodent, 444
 sheep, 449
 central corneal thickness, changes in, 442
 corneal graft rejection
 clinical criteria, 440–441
 from animal models, 441–443
 in vivo and post-mortem assessment, 438–440
 Enzymatic digestion, 428
 Epidermal growth factor (EGF), 14, 18, 28, 320, 335
 Epidermal stem cell, 128
 Epithelial basement membrane (EBM), 18
 Epithelial cell culture
 assessment
 cell counting and viability, 90
 colony forming efficiency assays, 90–91
 histology and immunostaining, 89–90
 measure explant outgrowth expansion, 90
 human amniotic membrane, 87–89
 limbal explant culture, 87
 biopsy, 87
 culture medium preparation, 84
 HAM construct preparation, 85
 single cell suspension method, 83
 3T3 fibroblast co-culture
 from frozen stock initiation, 84
 frozen layers preparation, 84
 frozen stocks preparation, 84
 maintenance and subculture, 84
 Epithelial keratinisation, 79
 Epithelial mesenchymal transition (EMT), 456, 467
 Epithelial regeneration, 479–480
 Epithelial stem cell, corneal epithelium regeneration
 amniotic membrane, 128
 epidermis, 128
 hair follicle, 128
 oral mucus, 127–128
 umbilical cord lining, 129
 Epithelial wound healing, 16–17
 Ethylenediamine tetra-acetic acid (EDTA), 428
 European Medicines Agency (EMA), 30, 93
 Ex vivo expansion, 83
 corneal endothelial regeneration, 466–467
 Exosomes, 413
 Extracellular matrix (ECM), 24, 351, 429
 Extracorneal stem cell
 corneal endothelium regeneration, 135
 embryonic and induced pluripotent stem cells, 135–136
 mesenchymal stem cells, 138
 mesothelial cell, 138–139
 neural crest stem cells, 137
 skin-derived precursor, 137
 vascular endothelial progenitor, 137–138
 corneal epithelium regeneration, 124

- epithelial stem cell, 127–129
 - immature dental pulp stem cell, 130–131
 - mesenchymal stem cell, 129–130
 - pluripotent stem cell, 124–127
 - corneal stroma regeneration, 131
 - embryonic stem cells and induced pluripotent stem cells, 131–133
 - mesenchymal stem cells, 133–134
 - oral stem cell, 134–135
 - Extraocular mesenchymal stem cell
 - for corneal epithelial damage, 253–254
 - experimental model
 - amniotic membrane, 249–250
 - with central corneal damage, 246
 - combined administration, 252–253
 - contact lens carrier, 250
 - fibrin matrix, 250
 - intraperitoneal administration, 248
 - intravenous administration, 246–248
 - mobilization of endogenous, 246
 - ocular topical administration, 248–249
 - polyamide 6/12 carrier, 251
 - poly-L-lactic acid carrier, 250
 - subconjunctival injection, 252
 - therapeutic potential
 - immunomodulatory ability, 240–244
 - in vitro* and *in vivo* studies, 233
 - tissue homing capacity, 244–246
 - transdifferentiation capacity, 234–237
 - trophic activity, 237–240
 - Extraocular stem cell
 - adipose derived adult mesenchymal stem cell, 405
 - bone marrow mesenchymal stem cell, 404
 - embryonic stem cell, 405
 - induced pluripotent stem cell, 406
 - umbilical cord mesenchymal stem cell, 405
 - Eyelid abnormalities, 295
 - Eye-platelet rich plasma (E-PRP), 325–326, 332
- F**
- Ferromagnetic material, 492
 - Fetal calf serum, 432
 - Fibrin gel, 250
 - Fibroblast growth factor (FGF), 15, 464
 - Fibronectin, 321
 - Fluorescence ubiquitination cell cycle indicator (Fucci), 304
 - Fluorochromes, 440
 - Foetal tissue, 477
 - Food and Drug Administration (FDA), 30
 - Fuchs endothelial corneal dystrophy (FECD), 20, 167, 463, 465, 466
 - Future stem cell based therapy, 164
 - corneal endothelium, 166–167
 - corneal epithelial cell
 - differentiated cell source, 164–166
 - from pluripotent stem cell, 164
 - corneal stroma, 166
 - purified LSC, 166
 - surface ectoderm-derived cell, 166
- G**
- Gap junctions (GP), 178, 421–422
 - Gelatin, 489
 - Gelatin disc, 447
 - Gene therapy medicinal product (GTMP), 49
 - Glucocorticoids, 294
 - Glycocalyx, 4
 - Glypican 4, 422
 - Gold nano-rods, 440
 - Good manufacturing practice, 91
 - GPC4, 117
 - GRIP1, 424
 - Growth factors (GF), 14, 464
 - epidermal growth factor, 320
 - function, 319
 - platelet-derived growth factor, 319–320
 - synthesize, 319
 - transforming growth factor beta, 320
 - vascular endothelial growth factor, 321
 - Guanine nucleotide exchange factors (GEFs), 465
- H**
- Hair follicle stem cell (HFSC), 128
 - HCEnC, *see* Human corneal endothelial cell (HCEnC)
 - Hemangioblast, 419
 - Hematopoietic markers, 8
 - Hemidesmosomes, 178
 - Hemoderivatives, 292
 - Heparin, 447
 - Hepatocyte growth factor (HGF), 15, 28, 464
 - Herpes simplex virus type-1 (HSV-1), 23
 - Holoclar®, 51
 - Homeostasis, in stroma, 145
 - HTR1D, 424
 - Human adult adipose tissue, 404
 - Human adult corneal limbal epithelial cell (HLEC), 127
 - Human adult dental pulp cells (hDPCs), 134
 - Human adult dermal fibroblast (HDF), 127
 - Human amniotic membrane (HAM), 85–89, 198, 284
 - Human bone marrow-MSC (hBM-MSC), 138
 - Human corneal endothelial cell (HCEnC), 485, 487, 489, 492
 - cellular and regenerative therapies, 110
 - culture media, 430–432
 - culture conditions
 - functional cell marker, 117–118
 - growth media, 112–116
 - surface, 116–117
 - endothelial progenitor cell, 110–112
 - extracellular matrix, 429, 430
 - immortalized cell lines, 428
 - injection, 491, 494
 - isolation, 112, 428
 - morphology of, 439
 - native, 110
 - primary, 427
 - sources, 427–428
 - stem cells, 427–428
 - substrates, 429–430
 - tissue engineering, 426–432

Human eye, 299
 Human limbal-derived stromal/mesenchymal stem cell (hLMSC), 395–398
 Human mesenchymal stem cells (hMSCs), 46
 Human umbilical cord
 cross-section of, 478
 stem cells, 478–479
 Human umbilical cord blood mesenchymal stem cells (hUCB MSCs), 469
 Hyaluronic acid, 489
 Hydrogel, 489

I

Immature dental pulp stem cells, 130
 Immune cells, 8
 Immunohistochemistry, 422
 Immunosuppression, 241
 Impression cytology, 282
 In vivo confocal microscopy (IVCM), 105, 282
 In vivo laser scanning confocal microscopy (IVCM), 301
 In vivo stimulation
 pharmacological treatment
 growth factors, 464
 ROCK inhibitors, 465
 surgical treatment, 465–466
 Indirect cell labeling methods, 440
 Induced pluripotent stem cell (iPSC), 111, 394, 406, 468, 478
 corneal endothelium regeneration, 135
 corneal epithelium regeneration, 127
 corneal stroma regeneration, 131–133
 mechanisms for reprogramming, 266–269
 Inflammation
 local, 294
 systemic, 295
 Insulin-like growth factor (IGF), 16, 18, 28
 Integrins, 14
 Interleukin 1 α (IL-1 α), 14
 International Society for Cellular Therapy, 237
 Intracellular carbonic anhydrase pathway, 422
 Intrastromal implantation, 407–409
 Intravenous injection, 412

J

Junctional adhesion molecules (JAMs), 423

K

Keratin, 304
 Keratinocytes growth factor, 28
 Keratinocyte growth factor 1 (KGF-1), 15
 Keratoconus
 characteristic, 363
 methods (*see* Confocal microscopy)
 patients, 364
 treatment, 363
 Keratocyte(s), 8, 26, 131, 353, 480
 activation, 145

 automated cell counting, 371
 collagen II production, 150
 differentiation, 146
 manual cell counting, 371
 morphology of, 369
 treatment, 149–153
 untapped potential of, 147, 149
 Keratocyte differentiation medium (KDM), 102
 Keratocyte progenitor cells (KPC), 300
 Kerato-epithelioplasty, 191
 Keratolimbic allograft (KLAL), 158
 Keratoplasty, 99, 227–228
 KLAL, *see* Keratolimbic allograft (KLAL)

L

Lagophthalmos, 295
 Lens epithelial cell-conditioned medium (LECCM), 111, 481
 LESC, *see* Limbal epithelial stem cell (LESC)
 Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), 456
 Lid abnormality repair, 295–296
 Lifitegrast, 294
 Limbal cells, 299
 Limbal epithelial crypts (LEC), 180–183
 Limbal epithelial stem cell (LESC), 6, 57, 77
 identification, 58
 isolation methods
 amniotic membrane, 63
 culture media, 60–62
 culture onto ECM coated surface, 63
 explant culture, 62
 feeder cells, 60–62
 silk fibroin, 63
 single-cell suspension culture, 62
 sphere-forming assay, 62
 tissue preparation, 60
 properties, 58
 Limbal explant biopsy, 87
 Limbal explant culture, 87
 Limbal niche, 77
 Limbal stem cell (LSC), 155, 191, 263–266, 299–300, 479
 Limbal stem cell deficiency (LSCD), 25, 78, 232, 277, 300, 479
 aetiology, 78, 277
 cause and manifestation, 213–214
 characteristics, 80
 conjunctivalisation, 301
 destruction, 300
 epidemiology, 79, 221
 grafting procedures, 480
 impression cytology, 300
 in vivo laser scanning confocal microscopy, 301
 management, 80–83
 regeneration of limbus, 302
 semiology, 79–80
 slit lamp examination, 300
 treatment, 214, 221–223, 301–302

- Limbal stem cell failure (LSCF), management, 225–226
 Limbal transplantation, 195
 allograft, 202–208
 autograft, 198–202
 classification, 194–195
 conjunctival, 195–198
 history, 191–194
 Limbus, 6
 Living-related conjunctival limbal allograft (Lr-CLAL), 158–160
 Local inflammation
 cyclosporine/tacrolimus, 294
 lifitegrast, 294
 steroids, 294
 Lr-CLAL, *see* Living-related conjunctival limbal allograft (Lr-CLAL)
 LSCD, *see* Limbal stem cell deficiency (LSCD)
- M**
- Macula adherens, 177
 Massive injury, 57
 Matrix metalloproteinases (MPPs), 14
 Medical therapy, 221
 Membrane-bound Na⁺, K⁺ -ATPase sites, 422
 Mesenchymal stem cell (MSC), 25, 42, 101, 123, 233
 autologous *vs.* heterologous, 412
 corneal endothelium regeneration, 138
 corneal epithelium regeneration
 adipose tissue, 130
 bone marrow, 129
 fetal tissue, 130
 mesenchymal-to-epithelial transition, 129
 corneal stroma regeneration
 adipose tissue, 133
 bone marrow, 133
 umbilical cord, 134
 exosome, (*see also* Extraocular mesenchymal stem cell), 413
 immune modulatory characteristics, 241
 immunomodulatory properties, 242–244
 types, 403
 Misdirected lashes, 296
 Mitomycin C inhibits, 18
 Modified embryonic stem cell medium (MESCM), 432
 MRGPRX3, 424
 Mucin-expressing cord lining epithelial cell (CLEC-muc), 480
 Mucopolysaccharides, 352
 Mucosa transplantation, 208–209
 Multipotent, 42
 Multipotent stem cell, 42, 111, 469, 477
 Mycophenolate mofetil, 295
 Myofibroblast, 392
- N**
- National Programme for Control of Blindness (NPCB), 390
 Native human corneal endothelial cells, 110
 N-cadherin, 468, 481, 482
 Negative HCEnc markers, 117
 Nerve growth factor (NGF), 15, 18, 28
 Neural cell adhesion molecule (NCAM), 423
 Neural crest cell (NCC), 271, 419, 420
 Neural crest-derived progenitor (NCDP), 167
 Neural crest progenitors (NPCs), 135
 N-isopropylacrylamide-co-glycidylmethacrylate (NGMA), 487
 Non-enzymatic digestion, 428
- O**
- Occludin, 177
 Ocular surface (OS), 176
 ecosystem restoration, 223
 epithelium
 basement membrane, 178–179
 cell attachment, 177–178
 conjunctiva, 183–186
 function, 176
 limbus and limbal, 179–183
 superficial flat cell, 176
 implantation, 406–407
 optical polish, 176
 reconstruction of, 226
 translational application on, 269–271
 transparent cornea, 176
 Oligopotent stem cells, 477
 Opioid growth factor (OGF), 29
 Optical coherence tomography (OCT), 282, 301, 438, 445
 OptiMEM-I based media, 112
 Oral mucus, 127
 Oral mucosa transplantation, 208
 Oral mucosa uses, 226
 Oral stem cell, 134
 Osmotic gradient, 422
 Oxidative stress protection, 239
- P**
- Palisades of Vogt, 6–7, 179, 180
 Palpebral conjunctiva, 184
 Penetrating keratoplasty (PK), 426, 437, 464
 Peptide amphiphiles (PA), 27
 Pericellular matrix from human decidua-derived mesenchymal cells (PCM-DM), 116
 Periocular mesenchymal progenitors (POMPs), 135
 Photorefractive keratectomy (PRK), 18
 Placental stem cell, 42
 Platelet(s)
 alpha granule, 318
 blood derivative
 inflammation, 323–324
 properties, 321–323
 discovery, 317
 electron microscopy, 318
 function, 318
 physiological condition, 318
 Platelet-derived growth factor (PDGF), 15, 28, 319–320, 335

- Platelet-rich plasma (PRP), 321
 antimicrobial activity, 324
 autologous serum, 327–328
 blood derivative, 324
 clinical applications, 328–331
 closed system, 326
 ANGEL®, 327
 PRGF Endoret®, 327
 RegenKit® BCT, 326
 E-PRP, 325–326
- Pluripotency of iPSCs, 52
- Pluripotent stem cell, 42, 111, 477
 corneal epithelium regeneration
 embryonic stem cell, 124–127
 induced, 127
- p75 neurotrophin receptor (p75NTR), 111
- Poly (glycerol sebacate)-poly (ε-caprolactone) (PGS-PCL), 490
- Poly(*N*-isopropyl acrylamide), 430, 466, 487
- Polyamide nanofiber scaffold, 251
- Polycaprolactone (PCL), 466
- Poly-L-lactic acid carrier, 250
- Polymegathism, 421
- Polymorphism, 421
- Polysaccharide-based materials, 27
- Poly (vinylidene fluoride) membrane, 447, 466
- Poly(vinyl methyl ether) (PVME), 487
- Post-mortem techniques, 438
- Pre-Descemet's layer (PDL), 355–359
- PRGF Endoret®, 327
- Primordium, 271
- Proliferating cell nuclear antigen (PCNA), 310
- Pterygium, 157
- Pump function, 422
- Pump-leak mechanism, 422
- Q**
- Quality assurance, 399
- Quality system approach, 400
- Quantum dots, 440
- R**
- Recombinant human collagen (RHC), 29
- Regenerative therapy, 123
- RegenKit® BCT, 326
- Rho-associated kinase (ROCK), 114, 426, 456–458, 465, 467, 492, 494
- Ripasudil, 465, 466
- Rostock Cornea Module (RCM) object, 364
- RTA 408 ophthalmic suspension, 464
- S**
- Scaffold, 26–28
 bioengineered, 27
 in ophthalmology, 26
 peptide amphiphiles, 27
 synthetic and natural based, 27
- Schirmer filter paper test, 282
- Schwalbe's line cells, 110, 427
- Sclerocorneal limbus, 263
- Secretory function, corneal endothelium, 422
- Serum free media (SFM), 46, 432
 cell morphology, 47
 cryopreservation, 47
 expansion, 47
 harvest protocol, 47
 immunophenotype analysis, 47
 isolation, 47
 multilineage differentiation potential, 47
 quality analysis, 47
 viability and cell proliferation, 47
- Severe stem cell deficiency, 227
- Silk fibroin (SF), 63, 489
- Silk fibroin graft, 445
- Simple limbal epithelial transplantation (SLET), 161, 214, 222
 advantages, 215
 complication, 217–218
 indication, 215–217
- Skin-derived precursors (SKPs), 137
- SLET, *see* Simple limbal epithelial transplantation (SLET)
- Slit lamp examination, 300
- Slit lamp microscopy, 438, 441
 of rabbit corneas, 446
 of rat corneas, 446
- Soft contact lenses, 293
- Somatic cell therapy medicinal product (SCTMP), 49
- Somatic stem cell, 123
- Specular microscopy, 438, 441
- Sphere(s)
 cell characteristics, 305
 direct compression injury of, 307, 308
 en masse migration, 306, 307
 from keratoconic cell, 312
 implantation
 into diseased central corneal tissue, 311
 into donor corneoscleral rims, 309
 migratory cells, 304
 on collagen substrate, 304–306
- Sphere formation, 303
- Sphere forming assay, 68, 302, 303
- Stage-specific embryonic antigens (SSEAs), 45
- Stem cells, 179
 anterior chamber injection of, 411
 advanced therapies with, 48–51
 and cancer, 51–52
 CEC progenitor cell, 469
 cell membrane markers, 45
 characterization, 45
 classification
 potentiality, 42
 source, 41
 concepts, 41
 culture, 46–48
 intracellular markers, 45
 intrastromal implantation of, 407–409
 intravenous injection of, 412
 marker, 310
 multipotent, 469, 477
 non-coding RNAs, 45
 ocular surface implantation of, 406–407

- oligopotent, 477
 - pluripotent, 468, 477
 - properties, 477
 - differentiation, 44
 - immunomodulation and immunogenicity, 44
 - self-renewal program, 42
 - spheres
 - isolation of sphere with mixed potential, 302–313
 - keratocyte progenitor cells, 300
 - limbal stem cell, 299–300
 - limbal stem cell deficiency, 300–301
 - regeneration of limbus, 302
 - stromal stem cells, 300
 - treatment, 301–302
 - sources
 - adult tissue, 478
 - embryonic tissue, 477
 - foetal tissue, 477
 - induced pluripotent stem cells, 478
 - totipotent, 477
 - transplantation, 215
 - types, 123
- Steroids**
- local inflammation, 294
 - systemic inflammation, 295
- Steroid-sparing immunosuppression, 295**
- Stevens-Johnsons syndrome (SJS), 79**
- Stroma, 13**
- Bowman's layer, 350
 - corneal transparency, 359–360
 - extracellular matrix, 351–352
 - glycosaminoglycan, 352
 - keratocyte, 353–355
 - nerves, 355
 - pre-descemets layer, 355–359
- Stromal keratocytes, 428**
- Stromal regeneration, 480–481**
- Stromal stem cells, 300**
- Stromal wound healing, 17–18**
- Structure-function relationships, 24**
- Subconjunctival injection, 252**
- Sulforaphane, 464**
- Superficial corneal epithelial cells, 178**
- Superparamagnetic microspheres, 445**
- Synthetic cell carriers, 489**
- Systemic immunosuppressive therapy, 295**
- Systemic inflammation, 295**
- Systemic toxicity test, 152**
- T**
- Tacrolimus, 294**
- TAG-2A12, 117**
- Tear film health**
- amniotic membrane, 293
 - hemoderivatives, 292
 - MGD and blepharitis treatment, 292
 - minimizing drop toxicity, 293
 - punctal occlusion, 293
 - soft and scleral contact lenses, 293
 - tear supplementation, 291
- Tenascin C, 182**
- Terminally differentiated cells (TDC), 78**
- Tight junctions (TJ), 422**
- Tissue engineered product (TEP), 49**
- Tissue engineering (TE)**
- clinical experiences, 29–30
 - corneal substitute
 - bioactive molecules, 29
 - cells, 25
 - scaffolds, 26–28
 - definition, 24
 - international regulations, 29–30
- Tonopen, 152**
- Topical glucocorticoids, 294**
- Total limbal stem cell deficiency (TLSCD), 80**
- Totipotent stem cells, 42, 477**
- Trabecular meshwork (TM), 491**
- Traditional corneal grafting techniques, 278**
- Transcription factor p63 ($\Delta Np63\alpha$), 266**
- Transforming growth factor beta (TGF- β), 15, 28, 320**
- Transient amplifying cell (TAC), 78, 265, 391**
- Trypsin, 428**
- U**
- Umbilical cord, 478**
- blood, 138, 479
 - lining membrane, 479
 - stem cells in, 478
- Umbilical cord blood endothelial progenitor cells (UCBEPSCs), 482**
- Umbilical cord lining epithelium, 129**
- Umbilical cord mesenchymal stem cell (UCMSC), 405, 480**
- corneal opacification, 481
 - in Lumican deficiency, 481
 - in mucopolysaccharidosis VII, 481
- Umbilical cord stem cell, 42**
- Unipotential stem cell, 42**
- Urokinase-Type Plasminogen Activator (uPA), 14**
- V**
- Vascular endothelial growth factor (VEGF), 321, 336**
- Vimentin, 304, 310, 312, 468**
- Vogt's striae, 369**
- W**
- Wharton's jelly, 479**
- Wharton's jelly of the umbilical cord (WJ-MSCs), 236**
- Wing cells, 3**
- X**
- Xenogeneic grafts, 441, 444**
- Z**
- ZO-1, 481, 482**
- ZP4, 424**